- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
- Interventions
- bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, dexamethasone, filgrastim, pegfilgrastim, Autologous stem cell transplantation (ASCT)
- Drug · Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 1,406
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Preeclampsia
- Interventions
- Apheresis using Liposorber LA-15 System
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
- Interventions
- bleomycin sulfate, filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2006
- U.S. locations
- 149
- States / cities
- Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Sargramostim
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 22 more
- Conditions
- Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Quality-of-Life Assessment, Thiotepa, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 2 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 129
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 1,377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
- Conditions
- Lymphoma
- Interventions
- Rituximab, Cytarabine, Dexamethasone, Leucovorin, Methotrexate, Procarbazine, Vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 68
- States / cities
- Stanford, California • Gainesville, Florida • Jacksonville, Florida + 51 more
- Conditions
- Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Rabies Human
- Interventions
- Rabies Vaccine, Metronidazole, Vancomycin, Neomycin Sulfate
- Biological · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Decatur, Georgia
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 3,154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2021
- U.S. locations
- 208
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Indinavir sulfate, Ritonavir, Ethambutol hydrochloride, Clarithromycin, Rifabutin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1999
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide Phosphate, Isotretinoin, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Thiotepa, Vincristine Sulfate, Vorinostat
- Radiation · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Months to 47 Months
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 10 more
- Conditions
- HIV Infections, Tuberculosis
- Interventions
- Atazanavir, Rifampin, Ritonavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2007
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Columbus, Ohio • Nashville, Tennessee
- Conditions
- Asthma
- Interventions
- Magnesium Sulfate, Placebo
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 2 Years to 20 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Cystic Fibrosis, Iron Deficiencies, Iron Deficiency Diseases
- Interventions
- IV Repletion, PO Repletion
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Indianapolis, Indiana • Kansas City, Kansas + 5 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- AVP-786, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 45
- States / cities
- Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
- Conditions
- Sore Throat, Post-Operative Sore Throat
- Interventions
- Zinc, Placebo
- Dietary Supplement
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Ritonavir, Delavirdine mesylate
- Drug
- Lead sponsor
- Agouron Pharmaceuticals
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- filgrastim, graft-versus-tumor induction therapy, rituximab, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, cytarabine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- Nevirapine, Nevirapine + Atazanavir/Ritonavir, Atazanavir + Ritonavir
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 2
- States / cities
- Pomona, California • Seattle, Washington
- Conditions
- HIV Infections
- Interventions
- BMS-955176, Atazanavir (ATV), Ritonavir (RTV), Dolutegravir (DTG), Tenofovir (TDF)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Los Angeles, California • Palm Springs, California + 13 more
- Conditions
- Leukemia
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 1 Year to 20 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Amarillo, Texas
- Conditions
- Leukemia, Lymphoma
- Interventions
- filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, Allopurinol
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 31
- States / cities
- San Diego, California • Lewes, Delaware • Newark, Delaware + 25 more